Extended interval dosing of natalizumab: is efficacy preserved?

被引：0

作者：

Clerico, M. ^{[1
]}

Signori, A. ^{[2
]}

De Mercanti, S. ^{[1
]}

Cordioli, C. ^{[3
]}

Signoriello, E. ^{[4
]}

Lus, G. ^{[4
]}

Maniscalco, G. T. ^{[5
,6
]}

Curti, E. ^{[7
]}

Lorefice, L. ^{[8
]}

Cocco, E. ^{[8
]}

Nociti, V. ^{[9
]}

Mirabella, M. ^{[9
]}

Baroncini, D. ^{[10
]}

Landi, D. ^{[11
]}

Mataluni, G. ^{[11
]}

Petruzzo, M. ^{[12
]}

Lanzillo, R. ^{[12
]}

Gandoglia, I. ^{[13
]}

Laroni, A. ^{[13
]}

Frangiamore, R. ^{[14
]}

Sartori, A. ^{[15
]}

Cavalla, P. ^{[16
]}

Costantini, G. ^{[16
]}

Sormani, M. P. ^{[2
]}

Capra, R. ^{[3
]}

机构：

[1] Univ Torino, San Luigi Gonzaga Hosp, Neurol Unit, Clin & Biol Sci Dept, Orbassano, Italy

[2] Univ Genoa, Sect Biostat, Dept Hlth Sci, Genoa, Italy

[3] Spedali Civili Brescia, Multiple Sclerosis Ctr, Presidio Montichiari, Brescia, Italy

[4] Univ Naples 2, Dept Med Surg Neurol Metab & Aging Sci, Naples, Italy

[5] AORN A Cardarelli, Neurol Clin, Naples, Italy

[6] AORN A Cardarelli, Multiple Sclerosis Ctr, Naples, Italy

[7] Univ Parma, Dept Med & Surg, Neurol Associates Unit, Parma, Italy

[8] Univ Cagliari, Binaghi Hosp, Dept Med Sci & Publ Hlth, Multiple Sclerosis Ctr, Cagliari, Italy

[9] Fdn Policlin Univ Gemelli, Neurosci Area, Neurosci Aging Head & Neck & Orthopaed Sci Dept, Multiple Sclerosis Ctr, Rome, Italy

[10] ASST Valle Olona, Presidio Osped Gallarate, Ctr Sclerosi Multipla, Gallarate, Italy

[11] Policlin Tor Vergata, UOSD Ctr Riferimento Reg Sclerosi Multipla, Dipartimento Neurosci, Rome, Italy

[12] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Multiple Sclerosis Ctr, Naples, Italy

[13] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

[14] IRCCS Fdn, Dept Neuroimmunol & Neuromuscular Dis, Neurol Inst C Besta, Milan, Italy

[15] Azienda Osped Univ Osped Riuniti, Azienda Sanit Univ Integrata Clin Neurol, Neurol Unit, Trieste, Italy

[16] Torino Univ Hosp, Dept Neurosci, Citta Salute & Sci, Turin, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P587

引用

页码：282 / 283

页数：2

共 50 条

[31] Effectiveness and safety profile of the natalizumab extended interval dosing in a spanish cohort
Costa-Frossard, L.
Sainz De La Maza, S.
Monreal, E.
Gomez Lopez, A.
Fernandez-Velasco, J. I.
Walo Delgado, P.
Espino, M.
Villarrubia, N.
Masjuan, J.
Villar, L. M.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 278 - 278
[32] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS
Ryerson, Lana Zhovtis
Naismith, Robert T.
Krupp, Lauren B.
Charvet, Leigh
Liao, Shirley
Fisher, Elizabeth
De Moor, Carl
Williams, James R.
Licata, Stephanie
Campbell, Nolan
NEUROLOGY, 2021, 96 (15)
[33] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths
Zhovtis-Ryerson, L.
Naismith, R. T.
Krupp, L.
Charvet, L.
Su, R.
Fisher, E.
De Moor, C.
Williams, J.
Campbell, N.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 293 - 293
[34] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
Ryerson, Lana Zhovtis
Foley, John
Kister, Ilya
Frohman, Teresa
Pandey, Krupa
Lu, Xiaochun
Goldberg, Judith
Zuniga-Estrada, Guadalupe
Hoyt, Tammy
Jacob, April
Bacon, Tamar
Major, Eugene
Frohman, Elliot
NEUROLOGY, 2017, 88
[35] Extended dosing interval reduces risk of natalizumab-related PML
Reactions Weekly, 2019, 1772 (1) : 9 - 9
[36] Real world effectiveness of Natalizumab extended interval dosing in a French cohort
Pelle, J.
Briant, A.
Lebrun-Frenay, C.
Cohen, M.
Mondot, L.
De Seze, J.
Bigaut, K.
Collongues, N.
Kremer, L.
Ricard, D.
Bompaire, F.
Sallansonnet-Froment, M.
Ohlmann, C.
Ciron, J.
Biotti, D.
Pignolet, B.
Parienti, J.
Defer, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 207 - 207
[37] Mri activity and extended interval of natalizumab dosing: a multicenter italian study
Clerico, M.
De Mercanti, S. F.
Signori, A.
Iudicello, M.
Cordioli, C.
Signoriello, E.
Lus, G.
Bonavita, S.
Lavorgna, L.
Maniscalco, G. T.
Curti, E.
Lorefice, L.
Cocco, E.
Nociti, V.
Mirabella, M.
Baroncini, D.
Mataluni, G.
Landi, D.
Petruzzo, M.
Lanzillo, R.
Gandoglia, I.
Laroni, A.
Frangiamore, R.
Sartori, A.
Cavalla, P.
Costantini, G.
Sormani, M. P.
Capra, R.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 538 - 538
[38] Population pharmacokinetic modeling of natalizumab efficacy using body weight as a classification factor for extended interval dosing.
Muralidharan, K. K.
Subramanyam, M.
Evans, K.
Steiner, D.
Ho, P-R
Amarante, D.
Koendgen, H.
Elkins, J.
Nestorov, I.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 881 - 882
[39] Extended interval dosing for natalizumab continues to show excellent efficacy and safety: italian experience comparison to USA data
Ryerson, L. Zhovtis
Ruggero, C.
Rasia, S.
Foley, J.
Kister, I.
Frohman, T.
Weinstock-Guttman, B.
Pandey, K.
Pawate, S.
Bomprezzi, R.
Tornatore, C.
Okuda, D.
Smith, D.
Estrada-Zuniga, G.
Jacob, A.
Hoyt, T.
Frohman, E.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 797 - 798
[40] Natalizumab extended interval dosing: what about wearing-off effect?
Bernardes, Catarina
Fernandes, Catarina
Cunha, Carolina
Batista, Sonia
Nunes, Carla
Macario, Maria do Carmo
Sousa, Livia Maria
Correia, Ines
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1010 - 1011

← 1 2 3 4 5 →